News | Contrast Media | January 30, 2017

Controlled study finds injury risk is actually higher for patients receiving unenhanced CT or not receiving CT at all

CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

January 30, 2017 — Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be associated with chronic kidney disease, dialysis, kidney transplant or acute kidney injury, despite long-held fears to the contrary. The results of the largest controlled study of acute kidney injury following contrast media administration in the emergency department were published online in Annals of Emergency Medicine ("Risk of Acute Kidney Injury Following Intravenous Contrast Media Administration").

"Over 80 million doses of IV contrast media are administered every year, and in the emergency department it can be essential to accurately diagnose certain acute critical conditions," said lead study author Jeremiah Hinson, M.D., Ph.D., of Johns Hopkins University School of Medicine in Baltimore. "But physicians have had concerns that the contrast media causes serious kidney problems later on, with some studies showing contrast-induced nephropathy occurring in as many as 14 percent of patients receiving it. However, studies used to establish this risk were performed prior to the development of modern contrast reagents or without adequate controls. Using a controlled design in current context, we could not find an association between intravenous contrast media use and acute kidney injury."

Researchers studied five years of records for patients receiving CT with or without contrast-enhancement in the emergency department. Of all CT scans, 57.2 percent were contrast-enhanced. The probability of developing acute kidney injury was 6.8 percent for patients undergoing contrast-enhanced CT, 8.9 percent for patients receiving unenhanced CT and 8.1 percent for patients not receiving CT at all.

"While a well-controlled randomized prospective study is required to fully determine the contribution of intravenous contrast media to the development of acute kidney injury, our results clearly demonstrate that in emergency departments such as ours where practice patterns have evolved to protect patients' kidneys, contrast media is not associated with increased risk of kidney injury," said Hinson. "Our data also suggest that in cases where contrast-enhanced CT is indicated to avoid delayed or missed diagnosis of critical disease, the potential morbidity and mortality resulting from a failure to diagnose potentially life-threatening conditions likely outweigh any potential risk of kidney injury.”

For more information: www.annemergmed.com

Hinson, J.S., Ehmann, M.R., Fine, D.M., Fishman, E.K., et al. "Risk of Acute Kidney Injury After Intravenous Contrast Media Administration," Annals of Emergency Medicine. Published Jan. 25, 2017. DOI: http://dx.doi.org/10.1016/j.annemergmed.2016.11.021

Related Content

News | Coronavirus (COVID-19)

November 24, 2021 — Significant decreases in CT imaging for cancer persisted even after the peak of the COVID-19 ...

Time November 24, 2021
arrow
News | Lung Imaging

November 23, 2021 — Median Technologies announces new outstanding performance of its lung cancer screening (LCS) CADx1 ...

Time November 23, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 23, 2021 — Researchers at Yale University analyzing specialized MRI exams found significant changes in the ...

Time November 23, 2021
arrow
News | Interventional Radiology

November 23, 2021 — A minimally invasive ablation procedure offers long-term relief for patients who experience chronic ...

Time November 23, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 22, 2021 — Adolescents and young adults with post-concussive symptoms who suffered three to five concussions ...

Time November 22, 2021
arrow
News | Lung Imaging

November 19, 2021 — Lung cancer screening is recommended only for those who are at high risk for the disease — adults ...

Time November 19, 2021
arrow
News | Artificial Intelligence

November 18, 2021 — VIDA Diagnostics Inc. (VIDA) is further removing friction in respiratory clinical trials with the ...

Time November 18, 2021
arrow
News | Artificial Intelligence

November 17, 2021 — Lunit, a leading medical artificial intelligence (AI) provider, announced it has received U.S. Food ...

Time November 17, 2021
arrow
News | Radiation Therapy

November 17, 2021 — Radiation can be a powerful cancer therapy, but it doesn’t work for everyone. A new study identifies ...

Time November 17, 2021
arrow
News | Prostate Cancer

November 16, 2021 — A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 ...

Time November 16, 2021
arrow
Subscribe Now